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MaBACKGROUND In a previous randomized trial, we found that percutaneous coronary intervention (PCI) was not inferior
to coronary artery bypass grafting (CABG) for the treatment of unprotected left main coronary artery stenosis at 1 year.
OBJECTIVES This study sought to determine the 5-year outcomes of PCI compared with CABG for the treatment of
unprotected left main coronary artery stenosis.
METHODS We randomly assigned 600 patients with unprotected left main coronary artery stenosis to undergo PCI
with a sirolimus-eluting stent (n ¼ 300) or CABG (n ¼ 300). The primary endpoint was a major adverse cardiac or
cerebrovascular event (MACCE: a composite of death from any cause, myocardial infarction, stroke, or ischemia-driven
target vessel revascularization) and compared on an intention-to-treat basis.
RESULTS At 5 years, MACCE occurred in 52 patients in the PCI group and 42 patients in the CABG group (cumulative
event rates of 17.5% and 14.3%, respectively; hazard ratio [HR]: 1.27; 95% conﬁdence interval [CI]: 0.84 to 1.90;
p ¼ 0.26). The 2 groups did not differ signiﬁcantly in terms of death from any cause, myocardial infarction, or stroke as
well as their composite (8.4% and 9.6%; HR, 0.89; 95% CI, 0.52 to 1.52; p ¼ 0.66). Ischemia-driven target vessel
revascularization occurred more frequently in the PCI group than in the CABG group (11.4% and 5.5%, respectively;
HR: 2.11; 95% CI: 1.16 to 3.84; p ¼ 0.012).
CONCLUSIONS During 5 years of follow-up, our study did not show signiﬁcant difference regarding the rate
of MACCE between patients who underwent PCI with a sirolimus-eluting stent and those who underwent CABG.
However, considering the limited power of our study, our results should be interpreted with caution. (Bypass Surgery
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2199AB BR E V I A T I O N S
AND ACRONYM S
CABG = coronary artery bypass
grafting
CI = conﬁdence interval
HR = hazard ratio
MACCE = major adverse
cardiac or cerebrovascular
event(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
TVR = target vessel
revascularization
ULMCA = unprotected
left main coronary arteryP atients undergoing revascularization of un-protected left main coronary artery (ULMCA)stenosis are considered at high risk of adverse
cardiovascular events. Coronary artery bypass graft-
ing (CABG) had been considered the standard of
care for ULMCA stenosis (1). However, over the
past 20 years, improvements in stent technology
and an accumulation of operator experience have
increased the number of elective percutaneous coro-
nary interventions (PCIs) performed to treat UMLCA
stenosis (2–4). Subsequently, several large registries
and randomized, controlled studies have shown
that PCI with a drug-eluting stent and CABG had
comparable incidences of death, myocardial infarc-
tion (MI), or stroke (5–7). Thus, recent guidelines
considered PCI to be a potential alternative to
CABG for ULMCA stenosis (8). However, the durable
effect of PCI remains in debate, and there are limited
existing data from long-term studies comparing PCI
and CABG.SEE PAGE 2207We present the 5-year results of the PRECOMBAT
(Bypass Surgery Versus Angioplasty Using Sirolimus-
Eluting Stent in Patients With Left Main Coronary
Artery Disease) study.
METHODS
STUDY DESIGN AND PATIENTS. The study design
and methods of the PRECOMBAT trial were previously
reported (6). In brief, the PRECOMBAT trial was a
prospective, open-label, randomized trial conducted
at 13 sites in South Korea. Patients considered eligible
to participate in the study were older than 18 years of
age and had received a diagnosis of stable angina,
unstable angina, silent ischemia, or non–ST-segment
elevation MI. All patients had newly diagnosed
ULMCA stenosis (more than 50% diameter stenosis by
visual angiographic estimation) and had been judged
to be suitable candidates for either PCI or CABG. A
complete list of inclusion and exclusion criteria is
provided in the Online Appendix. Patients were
randomly assigned to undergo PCI with sirolimus-
eluting stents or CABG in a 1:1 ratio. The institu-
tional review board at each hospital approved the
protocol, and all patients provided written
informed consent.
The funder of the study had no role in study
design, data collection, data analysis, data interpre-
tation, or writing of the report. The corresponding
author had full access to all the data in the study and
had ﬁnal responsibility for the decision to submit for
publication.PROCEDURES. The procedures for PCI
and CABG were described previously (5).
Sirolimus-eluting stents were the default
drug-eluting stents used during PCI. Use of
intravascular ultrasound, adjunctive devices,
or glycoprotein IIb/IIIa inhibitors was at
the operator’s discretion. All patients under-
going PCI took aspirin plus clopidogrel (300-
mg loading dose) or ticlopidine (500-mg
loading dose) before or during the procedure.
After PCI, all patients were prescribed 100
mg/day aspirin indeﬁnitely and 75 mg/day
clopidogrel or 250 mg/day ticlopidine for at
least 1 year. During CABG, the internal
thoracic artery was preferred for bypass of the
left anterior descending artery. Medications
after CABG were given according to the policy of the
institution or the preference of the surgeon. During
the index procedure or repeated revascularization, the
decision of which lesion was to be revascularized was
at the operator’s discretion.
FOLLOW-UP AND ENDPOINTS. After PCI, all patients
were asked to undergo follow-up angiography 8
to 10 months after the procedure or earlier if they
were experiencing symptoms of angina. However,
routine follow-up angiography was not performed
for patients who underwent CABG. All other follow-
up assessments were performed at 1, 6, 9, and 12
months and yearly thereafter at a clinic visit or via a
telephone interview.
The primary endpoint was a major adverse cardiac
or cerebrovascular event (MACCE) (a composite of
death from any cause, MI, stroke, or ischemia-driven
target vessel revascularization [TVR]) after randomi-
zation. Secondary endpoints included the individual
components of the primary endpoint; a composite of
death, MI, or stroke; and clinically driven TVR.
Deaths were considered cardiac unless an unequivo-
cal noncardiac cause was established. MI was deﬁned
as the appearance of new Q waves and an increase in
the creatine kinase-myocardial band concentration to
more than 5 times the upper limit of the normal
range, if occurring within 48 h after the procedure or
as the appearance of new Q waves or an increase in
the creatine kinase-myocardial band concentration
to greater than the upper limit of the normal range,
plus ischemic symptoms or signs, if occurring more
than 48 h after the procedure. Stroke was deﬁned
as a sudden onset of neurological deﬁcit resulting
from vascular lesions of the brain and persisting
for more than 24 h. TVR, in which repeat revascu-
larization with either PCI or CABG was performed in
the treated vessel, was considered to be driven by
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2200ischemia if the stenosis of any vessel was at least
50% of the vessel diameter in the presence of
ischemic signs or symptoms or if the stenosis was
at least 70% of the vessel diameter, even in the
absence of ischemic signs or symptoms. Alterna-
tively, TVR was considered clinically driven when
the treated vessels had stenosis of at least 50% in
the presence of ischemic signs or symptoms. The
event adjudication committee, whose members were
blind to the study group assignments, assessed all
clinical endpoints.
STATISTICAL ANALYSIS. Assuming 13% incidence
of the primary endpoint in the CABG group, a
noninferiority margin of 7%, and use of a Z test
for hypothesis testing, the original PRECOMBAT
trial was designed to have 80% power to show the
noninferiority of PCI, with a 1-sided type I error rate
of 0.05. In this study, unless stated otherwise, all
analyses were performed on an intention-to-treat
basis. A descriptive analysis was performed by pre-
senting data as the mean  SD or number (%).
Continuous variables were compared with a Student
t test or Wilcoxon rank sum test, and categorical
variables were compared with chi-square or Fisher
exact test, as appropriate. Five-year outcomes were
deﬁned as events occurring within 1,825 days after
randomization. The number of events and theirDistribution in the PRECOMBAT Study at the 5-Year Follow-Up
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ain Coronary Artery Disease.cumulative incidence were presented as number (%),
with the latter estimated using the Kaplan-Meier
method and compared between the 2 groups using
the log-rank test of the time to the ﬁrst event after
randomization. Hazard ratios (HRs) and 95% conﬁ-
dence intervals (CIs) were estimated with the use of
Cox proportional hazards models. The proportional
hazards assumption was checked with a graphical log-
minus-log method. We also compared the primary
endpoint between the 2 groups using Cox regression
models with robust SEs to account for the clustering
effect of sites. The patients lost to follow-up were
included in the analyses for all outcomes by censoring
at the data of last follow-up. We assessed the con-
sistency of treatment effects in the pre-speciﬁed
subgroups using Cox regression models with tests
for interaction. For more explicit comparison with
contemporary studies and guidelines, we added a
subgroup analysis according to the SYNTAX tertile
from the SYNTAX (Synergy Between PCI With Taxus
and Cardiac Surgery) trial. All statistical analyses
were performed using IBM SPSS version 21 (IBM,
Chicago, Illinois). A 2-tailed p value <0.05 was
considered statistically signiﬁcant.
RESULTS
STUDY PATIENTS. Between April 2004 and August
2009, a total of 600 eligible patients were randomly
assigned to undergo PCI with sirolimus-eluting
stents (n ¼ 300) or CABG (n ¼ 300). Of those, 279
patients (93%) in the PCI group and 275 patients
(91.7%) in the CABG group completed 5 years of
follow-up (Figure 1).
Baseline demographic and lesion characteristics
were previously described (7). In brief, the mean
age of patients was 61.8  10.0 years in the PCI
group and 62.7  9.5 years in the CABG group; 228
patients (76.0%) in the PCI group and 231 patients
(77.0%) in the CABG group were male; 102 patients
(34.0%) in the PCI group and 90 patients (30.0%) in
the CABG group had medically treated diabetes, of
whom 10 (3.3%) and 9 (3.0%), respectively, needed
insulin; 223 patients (74.4%) in the PCI group and
213 patients (71.0%) in the CABG group had left
main plus multivessel involvement. The mean
SYNTAX score was 24.4  9.4 in the PCI group and
25.8  10.5 in the CABG group.
Selected procedural characteristics of the patients
are as follows. In the PCI group, intravascular
ultrasound was used in 91.2%; the mean number
of stents implanted in left main coronary lesions
and per-patient was 1.6  0.8 and 2.7  1.4,
respectively. In CABG patients, 63.8% underwent
TABLE 1 Study Outcomes at the 5-Year Follow-Up
Endpoint
PCI
(n ¼ 300)
CABG
(n ¼ 300)
Hazard Ratio
(95% CI) p Value
MACCE 52 (17.5)* 42 (14.3) 1.27 (0.84–1.90) 0.26
Death from any cause 17 (5.7) 23 (7.9) 0.73 (0.39–1.37) 0.32
Cardiac 11 (3.8) 20 (6.9) 0.54 (0.26–1.13) 0.098
Noncardiac 6 (2.0) 3 (1.1) 1.98 (0.49–7.91) 0.33
Myocardial infarction 6 (2.0) 5 (1.7) 1.20 (0.37–3.93) 0.76
Q-wave MI 4 (1.4) 3 (1.0) 1.33 (0.30–5.95) 0.71
Non–Q-wave MI 2 (0.7) 2 (0.7) 0.99 (0.14–7.06) 1.00
Stroke 2 (0.7) 2 (0.7) 0.99 (0.14–7.02) 0.99
Death, MI, or stroke 25 (8.4) 28 (9.6) 0.89 (0.52–1.52) 0.66
Repeat revascularization 38 (13.0) 21 (7.3) 1.86 (1.09–3.17) 0.020
TVR 36 (12.4) 18 (6.3) 2.05 (1.17–3.62) 0.011
Ischemia driven 33 (11.4) 16 (5.5) 2.11 (1.16–3.84) 0.012
Clinically driven 27 (9.3) 15 (5.2) 1.83 (0.97–3.44) 0.057
Death, MI, or ischemia-driven TVR 50 (16.8) 40 (13.7) 1.28 (0.85–1.94) 0.24
Values are n (%) unless otherwise indicated. *Percentages are Kaplan-Meier estimates from the intention-to-
treat analysis. A log-rank test was used to calculate p values. Ischemia-driven TVR was deﬁned as any repeat
revascularization with either PCI or CABG in the treated vessel having at least 50% diameter stenosis in the
presence of ischemic signs or symptoms or at least 70% diameter stenosis in the absence of ischemic signs
or symptoms. Clinically driven TVR excluded lesions without ischemic symptoms or signs from the ischemia-
driven TVR.
CABG ¼ coronary artery bypass grafting; CI ¼ conﬁdence interval; MACCE ¼ major adverse cardiac or cere-
brovascular event(s); MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; TVR ¼ target vessel
revascularization.
J A C C V O L . 6 5 , N O . 2 0 , 2 0 1 5 Ahn et al.
M A Y 2 6 , 2 0 1 5 : 2 1 9 8 – 2 0 6 Stenting Versus CABG for Left Main Stenosis
2201off-pump surgery; 93.6% underwent revasculariza-
tion of the left anterior descending artery with left
internal mammary artery.
Antiplatelet drug use was signiﬁcantly higher in
patients in the PCI group than in the CABG group
throughout the study period. At 5 years, signiﬁcantly
more patients in the PCI group were receiving
dual-antiplatelet therapy than in the CABG group
(Online Table 1).
STUDY ENDPOINTS. The cumulative incidences of
the clinical outcomes are described in Table 1,
the Central Illustration, and Figure 2. At 5 years, the
cumulative incidence of MACCE was 17.5% in the
PCI group and 14.3% in the CABG group (HR: 1.27;
95% CI: 0.84 to 1.90; p ¼ 0.26). Analysis after
adjustment for between-site variability showed
results similar to those from the original analysis
(HR: 1.27; 95% CI: 0.83 to 1.93; p ¼ 0.28). The rate of
the composite of death from any cause, MI, or stroke
was also similar between the 2 groups (8.4% and
9.6%, respectively; HR: 0.89; 95% CI: 0.52 to 1.52;
p ¼ 0.66), without signiﬁcant differences in the in-
dividual components (Central Illustration). Ischemia-
driven TVR was more likely to occur in the PCI
group than in the CABG group (11.4% and 5.5%; HR:
2.11; 95% CI: 1.16 to 3.84; p ¼ 0.012) (Figure 2). In a
landmark analysis (Online Figure 1), the risk of
ischemia-driven TVR in the PCI group was more
obvious 1 year after randomization. An analysis of an
as-treated basis is shown in Online Table 2. Deﬁnite or
probable stent thrombosis occurred in 2 patients,
with a 5-year cumulative incidence of 0.3%.
SUBGROUP. Formal testing for interactions showed
that the results of the comparison of the 5-year rate
of MACCE between PCI and CABG were consistent
across multiple subgroups except for those deﬁned
according to angiographic left main coronary artery
stenosis (>70% vs. 50% to 70%) (Figure 3). Across the
3 subgroups deﬁned by SYNTAX score tertiles, the
rates of MACCE and the composite of death from any
cause, MI, or stroke were not signiﬁcantly different
between the 2 groups (Online Table 3, Online
Figure 2). In the high SYNTAX score ($33) group,
the rate of ischemia-driven TVR was signiﬁcantly
higher in the PCI group than in the CABG group.
DISCUSSION
The PRECOMBAT study was a randomized trial
comparing PCI with drug-eluting stents and CABG,
focusing on patients with ULMCA stenosis. The
1-year outcomes of the study showed the non-
inferiority of PCI to CABG with respect to MACCE(7). The current 5-year results of the study showed
that there were no signiﬁcant differences in the rate
of MACCE between patients assigned to PCI with
sirolimus-eluting stents and those assigned to
CABG, which conﬁrmed and extended the results
observed at 1 year (Central Illustration). In addition,
the rate of the composite of death, MI, or stroke
was similar between the 2 groups. However,
ischemia-driven TVR occurred more frequently
in the PCI group than in the CABG group. These
results are supported by data from observational
studies (9–12), a small randomized study (13), and a
meta-analysis of patients with long-term follow-up
(14). Recently, 5-year outcomes of the left main
subgroup in the SYNTAX study also showed a
similar trend, with no differences in the rate of
MACCE between the PCI and CABG groups (15).
The rates of overall adverse events in our study
were lower than those reported in the SYNTAX study.
The main differences were that we used sirolimus-
eluting stents as the default stent, and we used
intravascular ultrasound in more than 90% of pa-
tients for stent optimization (16–18). We considered
reasonably incomplete, but functionally adequate
stent implantation in the non–left main coronary
artery stenosis to avoid an excess of stent and related
events (19). In addition, differences in patient char-
acteristics, presentation, and lesion complexity may
be possible contributing factors. Nevertheless, the
FIGURE 2 Kaplan-Meier Cumulative Event Curves for the Individual Clinical Events at the 5-Year Follow-Up
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Abbreviations as in Figure 1.
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2202rate of TVR signiﬁcantly increased in the PCI group at
5 years compared with the CABG group. Given a
higher rate of repeat revascularization, even after the
use of second-generation drug-eluting stents for
ULMCA stenosis, frequent repeat revascularization
could be an inherent weakness of stent-related
treatments (20). However, the observed increase in
repeat revascularization in the PCI group did not
appear to translate into an increase in hard end-
points, such as death, MI, or stroke, although a
further study with longer follow-up and larger
number of subjects will be needed.
With respect to the occurrence of stroke, there
was no signiﬁcant difference between PCI and
CABG in our study. However, in the SYNTAX study,
although the rate of repeat revascularization was
signiﬁcantly higher in the PCI group, this was offset
by a signiﬁcantly higher rate of stroke in the CABGgroup. Consequently, the rate of MACCE was similar
between groups. Although the absence of any dif-
ference between the groups in our study is not
easily explained, possible causes are our study’s
low event rates and limited statistical power. In
addition, the different ethnicities in our study and
the SYNTAX study could be another contributing
factor.
Unlike the situation in multivessel disease (21,22),
both PCI and CABG showed similar rates of the com-
posite of death, MI, or stroke in patients with ULMCA
stenosis. The reason for this difference in outcomes
between ULMCA stenosis and multivessel stenosis is
unclear, but ULMCA stenosis might be a more
attractive target for PCI because of its larger caliber,
shorter lesion length, and lack of tortuosity compared
with multivessel disease. The ongoing EXCEL
(Evaluation of Xience Prime or Xience V Versus
FIGURE 3 Subgroup Analysis
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Subgroup analyses with hazard ratios and 95% conﬁdence intervals are shown for the primary endpoint of the composite of death of any cause, myocardial infarction,
stroke, or ischemia-driven target vessel revascularization among subgroups of patients randomized to undergo PCI or CABG. The p value for interaction represents the
likelihood of interaction between the variable and the relative treatment effect. CI ¼ conﬁdence interval; LM ¼ left main; MACCE ¼ major adverse cardiac or cere-
brovascular event(s); other abbreviations as in Figure 1.
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2203CABG for Effectiveness of Left Main Revasculariza-
tion) trial comparing a 3-year composite endpoint of
death, MI, or stroke in patients treated with PCI using
second-generation drug-eluting stents and CABG
will provide important information in this regard.
Current clinical guidelines have adopted the
SYNTAX score to aid in selection of the appropriate
revascularization strategy for ULMCA stenosis (8).
However, our study showed that the SYNTAX score
tertile did not discriminate the more appropriatestrategy between treatments. Even in patients with
the highest baseline SYNTAX scores ($33), no signif-
icant difference between treatment groups for the
primary endpoint was reported. Although this might
be primarily due to insufﬁcient statistical power, the
utility of the SYNTAX score for this purpose still
needs to be evaluated (21,23–25). Recent approaches
combining anatomic and clinical factors could be
promising for a more accurate personalized assess-
ment of patient risk (25).
CENTRAL ILLUSTRATION Stenting Versus CABG for LeftMain Stenosis: Kaplan-Meier Cumulative Event Curves of the
Primary Endpoint and the Major Secondary Endpoint at the 5-Year Follow-Up
Ahn, J-M. et al. J Am Coll Cardiol. 2015; 65(20):2198–206.
(Top)Thecumulative incidenceofmajoradversecardiacor cerebrovascularevents (thecompositeofdeathfromanycause,myocardial infarction,stroke,
or ischemia-driven target vessel revascularization). (Bottom) The composite of death of any cause, myocardial infarction, or stroke. CABG¼ coronary
artery bypass graft; PCI¼ percutaneous coronary intervention.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Over 5 years,
outcomes of revascularization for patients with LMCA stenosis
managed by PCI did not differ signiﬁcantly in terms of the
composite endpoint of all-cause mortality, MI, stroke, or
target vessel revascularization from those in patients undergoing
CABG surgery.
TRANSLATIONAL OUTLOOK: Additional studies of a larger
number of patients and longer follow-up are needed to provide
adequate statistical power to establish the optimal revasculari-
zation strategy for the prevention of death, MI, and stroke in
patients with LMCA stenosis.
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M A Y 2 6 , 2 0 1 5 : 2 1 9 8 – 2 0 6 Stenting Versus CABG for Left Main Stenosis
2205In the subgroup analysis, there was a signiﬁcant
interaction between angiographic stenosis of the
left main coronary artery and treatment strategies
for the primary endpoint. The reason was unclear,
and this unexpected ﬁnding is likely due to the play
of chance. In addition, patients with left main dis-
ease plus 3-vessel disease showed better outcomes
with CABG than with PCI, suggesting caution in the
use of PCI for left main disease in patients with
3-vessel coronary artery disease or advanced coro-
nary artery disease.
STUDY LIMITATIONS. First, although we tried to
enroll all comers, as in other randomized studies, it
was possible that we enrolled selected patients with
relatively low-risk proﬁles. Second, crossovers,
particularly from PCI to CABG, may have introduced
bias. Third, this study did not have adequate power to
compare hard endpoints, such as death, MI, and
stroke. Fourth, owing to the limited sample size, the
results of our subgroup analyses should be consid-
ered hypothesis generating at best. Fifth, the sys-
tematic performance of follow-up angiography in
the PCI group may have increased the rate of TVR.
Smaller and statistically insigniﬁcant HR for clinically
driven TVR, compared with that for ischemia-driven
TVR, probably supports this hypothesis. Finally,
clinical outcomes may have been affected by unequal
use of antiplatelet agents between the 2 groups
(Online Table 1).
CONCLUSIONS
During the 5-year follow-up, our study did not
show a signiﬁcant difference in the rate of MACCE
between patients who underwent PCI with asirolimus-eluting stent and those who underwent
CABG, supporting current guidelines stating that
left main stenting is a feasible revascularization
strategy for patients with suitable coronary anatomy.
However, considering the limited power of our study,
our results should be interpreted with caution.
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